Michael Vi/iStock Editorial via Getty Images
- RNA medicine developer Ascidian Therapeutics announced a research and licensing agreement with Roche (OTCQX:RHHBY) (OTCQX:RHHBF) on Tuesday to develop treatments targeted at neurological diseases.
- As part of the deal, Roche (OTCQX:RHHBF) will receive exclusive rights to Ascidian’s RNA exon editing technology to target specific undisclosed neurological targets.
- The duo will jointly conduct certain preclinical activities before the Swiss pharma giant takes over the clinical development, manufacturing, and commercialization of drugs resulting from the collaboration.
- In exchange, Boston-based Ascidian will receive $42M upfront, up to $1.8B in research, clinical, and commercial milestone payments, and royalties on global commercial sales.
- The agreement will not preclude Ascidian from developing programs against other neurological targets in partnership with other parties or using its internal resources.
Source link
Related Articles
